Satellos Bioscience Inc (MSLE)

$MSLE what if I told you this stock goes up once the name of the new investor comes out?

$MSLE Prophet Trust-Me-Bro 🤣

$MSLE man am I a prophet or what? Investors are going to get wiped out. lol

$MSLE yup this ticker diluted share holders right away lol on the first day of Nasdaq listing. https://finance.yahoo.com/news/satellos-closes-us-57-2-220000126.html

$MSLE RS then followed by a $50 million offering that closed today along with warrants. lol. Just like clockwork. This ticker didn’t even miss a beat.

$MSLE That this hasn't raced down to the $10.10 offering price or below on no news is interesting. Sentiment is clear.

$MSLE This looks great, thanks for sharing!

$MSLE Price Prediction - arbitrage adjustment is a 2x to 3x so $25, then with positive randomized Ph2 data in 2H26 we should be looking at 4x on the $25 so $100 A $2.0B market cap which is in the zone with Wave, Dyne, Edgewise

$MSLE It looks like all went well with the listing. Great work. Let’s see if we get something going this Spring. Crazy K

$MSLE lol some saying SAT 3247 is revolutionary, Cmon, typical for biotech investor hype because it’s still an early stage investigational drug without proven long term efficacy in large trials. SAT 3247 has not proven to alter disease progression meaningfully! Data are from a very small, early phase studies. Phase 1, open label in adults and preclinical models. Functional improvements grip strength are preliminary signals, not definitive proof of broad muscle regeneration or long term benefit. DMD trials often show placebo effects or variability. True efficacy needs larger, longer, controlled studies, Phase 2 and 3. Many DMD therapies have promising early data but later fail to meet endpoints. I think this will be shorted back to pennies. It’s a got a long way to go. The drug has nothing to stand on except hype.

$MSLE Current Market Cap (USD) / Clinical Phase Avidity Biosciences (RNA): $11,262,000,000 P2 Edgewise Therapeutics (EWTX): $3,081,000,000 P2 Dyne Therapeutics (DYN): $2,766,000,000 P1/2 Wave Life Sciences (WVE): $2,498,000,000 P2 Sarepta Therapeutics (SRPT): $1,939,000,000 Commercial Capricor Therapeutics (CAPR): $1,345,000,000 BLA Keros Therapeutics (KROS): $535,000,000 P1 Regenxbio (RGNX): $523,000,000 BLA Solid Biosciences (SLDB): $508,000,000 P1/2 Satellos Bioscience (MSLE) $174,000,000 P2A

$MSLE SAT-3247 may be revolutionary because it aims to fix the muscle’s own repair system, not just replace dystrophin or slow damage, this is done with a once‑daily oral small molecule that is mutation‑agnostic and theoretically useful across all stages of DMD. Satellos’ core discovery is that DMD is also a disease of broken muscle stem cell behavior: dystrophin loss disrupts the “balanced” asymmetric division of satellite cells, so the muscle can’t properly repair itself. SAT-3247 restores this balance by targeting a dystrophin‑independent pathway, reframing DMD as a disorder that can be treated by rebooting regeneration rather than only adding dystrophin. SAT-3247 inhibits AAK1, which helps re‑establish the polarity across a satellite cell so one daughter remains a stem cell and the other becomes a progenitor that regenerates muscle. By “resetting” these divisions, the drug aims to maintain the stem cell pool while generating new muscle fibers, muscle regeneration back on in DMD.

$MSLE waiting for a dollar

$MSLE Hmmm someone is claiming a $75 share price in one year with no projected commercial product by then. I predict back to pennies. This is beyond hopium. Maybe after a Phase3 stat sig approval YES but without approval this NO. Shortie will be here soon after this RS. Guaranteed. Crazy to think otherwise.

$MSLE Well guys, looks like this is the new channel going forward. Lost my price predictions so let's do a new one? Have fun all 🤝

$MSLE elevator going down. Come on in. lol

$MSLE Satellos Bioscience reported its most recent cash position in the third quarter 2025, financial results ended September 30, 2025, released on November 14, 2025. Cash and cash equivalents, US$19.3 million Short term investments: US$15.3 million Total cash, cash equivalents, and short-term investments. US$34.6 million end of September 2025. Analysts and company statements from earlier 2025 estimated cash runway into 2026 or through key milestones like Phase 2 initiation. However, with burn rates around US $20-21 million annually the runway is likely sometime this year or sooner. Lots of going ons with this company, with the latest consolidation of 15 million shares and a lofty PPS of $12 that used to be 185 million shares with PPS in pennies. The time is ripe for the company to make money in lieu of the brave souls buying this pig. I can see the vultures dressed in bears circling, getting ready to pounce on this for the take down. This is bio where lots get slaughtered. GL.